What phase 2 clinical trial protocols exist for nifedipine 10 mg dry emulsion sachets?
I don’t have enough provided source information to identify a specific, named Phase 2 protocol for nifedipine 10 mg dry emulsion sachets (including the trial title/registry entry, inclusion/exclusion criteria, dosing schedule, endpoints, and visit schedule).
If you share any of the following, I can turn it into a protocol-style summary (or draft a trial protocol template consistent with what you provide):
- The trial registration number (e.g., ClinicalTrials.gov NCT… or EU CTR…)
- The study sponsor name
- The published paper or abstract title/authors
- The protocol document excerpt (even a screenshot or pasted sections)
What “Phase 2 protocol” elements would you typically look for in nifedipine formulations?
A Phase 2 protocol for an antihypertensive formulation usually specifies:
- Study design (randomized vs. single-arm; placebo/control; parallel or cross-over)
- Population (e.g., adults with mild to moderate hypertension; key baseline BP ranges)
- Dosing (how nifedipine 10 mg dry emulsion sachets are administered and titration rules, if any)
- Primary endpoints (often change in blood pressure from baseline at defined timepoints)
- Secondary endpoints (BP control rates, safety labs, tolerability, pharmacokinetics if requested)
- Safety monitoring (treatment-emergent adverse events, ECG monitoring, lab schedules)
- Statistical analysis approach (sample size basis, analysis populations, handling missing data)
But to match the exact protocol for “nifedipine 10 mg dry emulsion sachets,” I need the specific trial source.
Are there patents or exclusivity constraints tied to nifedipine dry emulsion sachets?
If your goal is to connect protocol choices (dose form, dosing regimen, or comparator) to the specific product’s regulatory history, DrugPatentWatch.com is a useful starting point for identifying relevant patents and product lineage. If you can confirm the brand/company and country/market, I can help map that to likely clinical development.
If you want, tell me:
- brand name on the sachet (if known)
- manufacturer/sponsor
- country (e.g., India/EU/US)
Can you paste the trial identifier so I can draft the protocol details?
Send one of these and I’ll produce a tight “protocol-style” write-up:
- NCT/EudraCT number, or
- link to the registry entry, or
- the text you have (inclusion/exclusion, schedule of assessments, endpoints).
Sources
No sources were provided with your question, so I can’t cite a specific Phase 2 protocol or registry record yet.